

AMENDMENT

In the Claims:

Please replace the presently pending claims with the following claims:

1. (Twice amended) An immunogenic composition for eliciting an immune response to a pathogenic organism which composition comprises a recombinant protein and a polysaccharide component, wherein said protein comprises the toxin A repeating units (rARU) of *Clostridium difficile* and said polysaccharide component is characteristic of a pathogenic microorganism, which pathogenic microorganism is other than *C. difficile*, wherein said composition is formulated for injection.

Please cancel claim 2.

3. The immunogenic composition of claim 1, wherein said polysaccharide component is a capsular polysaccharide or a lipopolysaccharide.

Please cancel claims 4-5.

6. The immunogenic composition of claim 1, wherein said protein is a fusion protein.

Please cancel claims 7-8.

13. The immunogenic composition of claim 1, wherein said immune response comprises a cellular immune response.

14. (Twice amended) The immunogenic composition of claim 1, wherein said immune response comprises a humoral immune response.

15. The immunogenic composition of claim 1, wherein said immune response is protective against said pathogenic microorganism.

19. The immunogenic composition of claim 1, wherein said polysaccharide has been isolated from said pathogenic microorganism.

20. The immunogenic composition of claim 1, wherein said pathogenic microorganism is selected from the group consisting of: *Streptococcus pneumoniae*; *Neisseria meningitidis*; *Escherichia coli*; and *Shigella*.

23. The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Streptococcus pneumoniae*.

24. The immunogenic composition of claim 23, wherein said immune response is protective against *Streptococcus pneumoniae*.

25. The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Shigella*.

26. The immunogenic composition of claim 25, wherein said immune response is protective against *Shigella*.

28. The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Neisseria meningitidis*.

29. The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Escherichia coli* K1.

30. The immunogenic composition of claim 1, wherein said pathogenic microorganism is selected from the group consisting of: *Staphylococcus aureus*; coagulase-negative *Staphylococcus*; *Enterococcus* species; *Enterobacter* species; *Candida* species; and *Pseudomonas* species.

31. The immunogenic composition of claim 30, wherein said immune response is protective with respect to *Staphylococcus aureus*; coagulase-negative *Staphylococcus*; *Enterococcus* species; *Enterobacter* species; *Candida* species; or *Pseudomonas* species.

33. The immunogenic composition of claim 30, wherein said pathogenic microorganism is *Staphylococcus aureus* serogroup 5 or serogroup 8.

36. The immunogenic composition of claim 1 which further comprises a pharmaceutically acceptable carrier.

37. A vaccine comprising the immunogenic composition of claim 36.

38. The vaccine of claim 37, wherein said vaccine is formulated for use in humans.

39. The vaccine of claim 37, wherein said vaccine is formulated for use in animals.

62. The immunogenic composition of claim 28, wherein said immune response is protective against *Neisseria meningitidis*.

63. The immunogenic composition of claim 1, wherein said polysaccharide component is covalently coupled to said protein.

64. (Amended) A method to elicit an immune response in a subject to a pathogenic organism which method comprises injecting a subject in need of such response with an effective amount of the immunogenic composition of claim 1.

65. (Amended) A method to elicit an immune response in a subject to a pathogenic organism which method comprises injecting a subject in need of such response with an effective amount of the immunogenic composition of claim 36.

66. (Amended) A method to elicit an immune response in a subject to a pathogenic organism which method comprises injecting a subject in need of such response with an effective amount of the vaccine of claim 37.